ThredUp Stock Slips 8% On Quarterly Results

Shares of ThredUp Inc. (TDUP) slipped over 8% in extended hours on Monday after the company reported its fourth-quarter results.

Fourth-quarter net loss was $17.9 million or $0.18 per share, compared to a loss of $17.0 million or $1.33 per share last year. On a per share basis, net loss narrowed due to higher number of shares outstanding for the quarter.

Revenues for the quarter rose to $72.9 million from $43.4 million last year.

Analysts polled by Thomson Reuters expected a loss of $0.17 per share on revenues of $69.97 million.

The company said active buyers rose 36% to 1.7 million and orders increased 69% to 1.7 million.

Looking forward, the company expects revenues of $70 million to $72 million and $330 million to $340 million for the first quarter and full year 2022, respectively. Analysts currently estimate revenues of $76.68 million and $333.05 million for the first quarter and full year, respectively.

TDUP closed Monday's trading at $7.55, up $0.53 or 7.55%, on the Nasdaq. The stock, however, slipped $0.64 or 8.48%, in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT